Page 68 - 2019_06-Haematologica-web

Ferrata Storti Foundation
Haematologica 2019 Volume 104(6):1150-1155
Chronic Myeloid Leukemia
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features
in chronic myeloid leukemia
Audrey Bidet,1 Stéphanie Dulucq,1 Thomas Smol,2,3 Alice Marceau-Renaut,4,5 Stéphane Morisset,6 Valérie Coiteux,7 Marie-Pierre Noël-Walter,7 Franck- Emmanuel Nicolini,6,8 Isabelle Tigaud,9 Isabelle Luquet,10 Stéphanie Struski,10 Baptiste Gaillard,11 Dominique Penther,12 Sylvie Tondeur,13 Nathalie Nadal,14 Eric Hermet,15 Lauren Véronèse,16 Delphine Réa,17 Carine Gervais,18 Olivier Theisen,19 Christine Terré,20 Pascale Cony-Makhoul,21 Christine Lefebvre,22 Jean-Baptiste Gaillard,23 Isabelle Radford24 Anne-Laure Vervaeke,1 Carole Barin,25 Elise Chapiro,26 Florence Nguyen-Khac,26 Gabriel Etienne,27 Claude Preudhomme,3,4,5 François Xavier Mahon27 and Catherine Roche-Lestienne2,3,5 on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).
1Laboratoire d’Hématologie, CHU Bordeaux; 2Institut de Génétique Médicale, Hôpital Jeanne de Flandre, CHU Lille; 3Centre de Recherche Jean-Pierre Aubert, UMR-S 1172, Université de Lille; 4Institut d’Hématologie, Centre de Biologie Pathologie Génétique, CHU Lille; 5Inserm, UMR-S 1172, Lille; 6Département d’Hématologie, Centre Léon Bérard, Lyon; 7Service des Maladies du Sang, Hôpital Claude Huriez, CHU Lille; 8Inserm U1052, Centre de Recherche en Cancérologie, Centre Léon Bérard, Lyon; 9Laboratoire de Cytogénétique et de Biologie Moléculaire, Service d'Hématologie Biologique - CBPAS, GHS - Hospices Civils de Lyon, Pierre-Bénite Cedex, France; 10Laboratoire d’Hématologie, Plateau Technique Hématologie-Oncologie, Institut Universitaire du Cancer de Tolouse Oncopole; 11Laboratoire Central d’Hématologie, Hôpital Robert Debré, Reims; 12Laboratoire de Génétique Oncologique, Centre de Lutte Contre le Cancer Henri Becquerel, Rouen; 13Laboratoire d’Hématologie–Cytogénétique, CHU Saint-Etienne, Hôpital Nord, Saint- Etienne Cedex 2; 14Laboratoire de Génétique Chromosomique et Moléculaire, Plateau Technique de Biologie, CHU de Dijon; 15Service d’Hématologie Clinique, CHU Estaing, Clermont-Ferrand; 16Laboratoire de Cytogénétique, CHU Estaing, Clermont-Ferrand; 17Service Clinique des Maladies du Sang, Hôpital St Louis, Paris; 18Laboratoire Régional de Cytogénétique Hématologique d’Alsace, CHU de Haute Pierre, Strasbourg Cedex; 19Laboratoire de Cytogénétique Hématologique, Plateau Technique Hôtel Dieu, Nantes; 20Laboratoire de Cytogénétique du Centre Hospitalier Valence, Le Chesnay; 21Service d’Hématologie, Centre Hospitalier Annecy-Genevois, Epagny Metz-Tessy; 22Unité de Génétique des Hémopathies, Institut de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble Cedex 9; 23Unité de Génétique Médicale et Cytogénétique, CHU de Nîmes; 24Laboratoire de Cytogénétique, Hôpital Necker – Enfants Malades, Paris; 25Laboratoire de Cytogénétique Onco-Hématologie, Hôpital Bretonneau, Tours; 26Service d’Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris et Sorbonne Université, Paris and 27Département d’Hématologie, Institut Bergonié, Bordeaux, France.
ABSTRACT
Clonal chromosome abnormalities in Philadelphia-negative cells could concern chronic myeloid leukemia patients treated by tyrosine kinase inhibitors. The European LeukemiaNet distin- guishes -7/del(7q) abnormalities as a “warning”. However, the impact of clonal chromosome abnormalities, and specifically those of -7/del(7q), in Philadelphia-negative cells on clinical outcomes is unclear and based on case-reports showing morphological dysplasia and increased risk of acute myeloid leukemia, suggesting the coexistence of chronic myeloid leukemia and high-risk myelodysplastic syndrome. The aim of this study was to determine whether the impact of -7/del(7q) clonal chromosome abnormal- ities in Philadelphia-negative cells on the clinical outcome is different from that of other types of abnormalities, and we argue for an underlying asso- ciated high-risk myelodysplastic syndrome. Among 102 chronic myeloid
Correspondence:
CATHERINE ROCHE-LESTIENNE
catherine.roche@chru-lille.fr
Received: October 8, 2018. Accepted: December 18, 2018. Pre-published: December 20, 2018.
doi:10.3324/haematol.2018.208801
Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: www.haematologica.org/content/104/6/1150
©2019 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or inter- nal use. Sharing published material for non-commercial pur- poses is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for com- mercial purposes is not allowed without permission in writing from the publisher.
1150
haematologica | 2019; 104(6)
ARTICLE